Related Experiment Video
Updated: Apr 20, 2026
Non-Invasive Endotracheal Administration of Lipopolysaccharide to Induce Acute Lung Injury in Rodents
Published on: December 5, 2025
Adjunctive dexamethasone therapy improves lung injury by inhibiting inflammation and reducing RIP3 expression during
Abstract:
Antibiotic-induced immunopathology associated with the release of bacterial cell wall components has been suggested to contribute to poor outcomes in bacterial pneumonia. Adjunctive systemic glucocorticoid steroid (GC) therapy for pneumonia has been a controversial issue. In the present study, we first found that dexamethasone (2.5 mg/kg/day) in combination with oxacillin was beneficial for improving lung injury in mice inoculated intratracheally with live Staphylococcus aureus, and did not interfere with bacterial clearance. Alleviation of lung injury was evidenced by attenuated lung pathology, reduced total protein levels, soluble receptor for advanced glycation end-products (sRAGE), tumor necrosis factor alpha (TNF-α), and keratinocyte chemoattractant (KC) and interleukin (IL)-6 in bronchoalveolar lavage fluid (BALF). It was further confirmed by inhibition of receptor interacting protein-3 (RIP3) expression in pulmonary tissues. As in the live S. aureus experiments, dexamethasone (2.5 mg/kg/day) improved lung injury in mice challenged with heat-killed S. aureus (HKSA). In conclusion, our results demonstrated that an appropriate dose of adjunctive dexamethasone (2.5 mg/kg/day) with oxacillin alleviated experimental S. aureus-induced lung injury via its inhibition of inflammatory cytokine release and RIP3 expression.
Insights
Dexamethasone combined with oxacillin improved lung injury in mice with Staphylococcus aureus pneumonia. This adjunctive steroid therapy reduced inflammation and lung damage without hindering bacterial clearance.
Area of Science:
- Immunology
- Pulmonary Medicine
- Pharmacology
Background:
- Antibiotic use in bacterial pneumonia can cause immunopathology due to bacterial cell wall components, potentially worsening outcomes.
- The efficacy of adjunctive systemic glucocorticoid steroid (GC) therapy for pneumonia remains controversial.
- Staphylococcus aureus is a significant pathogen in bacterial pneumonia, often requiring antibiotic treatment.
Purpose of the Study:
- To investigate the effects of adjunctive dexamethasone therapy on Staphylococcus aureus-induced lung injury in a murine model.
- To determine if dexamethasone influences bacterial clearance or exacerbates antibiotic-induced immunopathology.
- To elucidate the mechanisms by which dexamethasone may alleviate lung injury.
Main Methods:
- Mice were intratracheally inoculated with live or heat-killed Staphylococcus aureus.
- Mice received oxacillin alone or in combination with dexamethasone (2.5 mg/kg/day).
- Lung injury was assessed by histopathology, bronchoalveolar lavage fluid (BALF) analysis for protein, sRAGE, TNF-α, KC, and IL-6, and pulmonary tissue analysis for RIP3 expression.
Main Results:
- Dexamethasone combined with oxacillin significantly attenuated lung injury in mice challenged with live S. aureus.
- This combination therapy did not interfere with bacterial clearance.
- Reduced levels of total protein, sRAGE, TNF-α, KC, and IL-6 were observed in BALF, along with inhibited RIP3 expression in pulmonary tissues.
- Dexamethasone also improved lung injury in mice challenged with heat-killed S. aureus.
Conclusions:
- Adjunctive dexamethasone (2.5 mg/kg/day) with oxacillin effectively alleviated experimental S. aureus-induced lung injury.
- The therapeutic benefit is linked to the inhibition of inflammatory cytokine release and RIP3 expression.
- This study supports a potential role for carefully dosed glucocorticoids in managing severe bacterial pneumonia.
